Navigation Links
Process controlling T cell growth and production identified
Date:5/3/2009

HOUSTON (May 3, 2009) Identifying one of the processes that plays a role in nave and memory T-cells' growth and production could one day lead to better vaccines and possibly more effective cancer immunotherapy, said researchers at Baylor College of Medicine and Texas Children's Hospital in a report that appears in the current edition of Nature Immunology.

In previous work, Dr. Daniel Lacorazza, assistant professor of pathology at BCM, along with his research team, identified a transcription factor, ELF4, which regulates blood stem cells. A transcription factor is a protein that regulates how genes are translated into a form that leads to the making of the proteins associated with them.

"We knew ELF4 played a role in maintaining T cells," said Lacorazza, who is the principal investigator of the current study. "What we discovered was that ELF4 activates an inhibitor that leads to cell arrest, stopping naive T cells from proliferation."

A population of nave CD8 T-cell is always circulating in the body and maintained at a constant level. Memory T cells are created when nave CD8 T cells are activated to fight intracellular pathogens such as viruses or bacteria. The fight against infections prompts creation of memory T cells that then "remember" antigens or proteins found on cells infected with viruses or bacteria. In the future when same infections arise, memory T-cell enhances the body's ability to fight them.

Lacorazza and his research team focused on how ELF4 affected the process of inhibiting proliferation of CD8 T cells. Using mice generated to lack ELF4, researchers found that CD8 T-cells grew over time and acquired a "memory phenotype" without being exposed to any type of infections. At the same time, they determined that expression of the tumor suppressor gene called KLF4 was reduced in these mice.

"We discovered that ELF4 directly activates the tumor suppressor KLF4, which signals cell cycle arrest in nave CD8 T cells," Lacorazza said. "This inhibitory process is important to T cells because it stops them from proliferating out of control." Cell cycle arrest means the cells do not go through the normal events of their life cycles: growth, replication and division. The description of cell intrinsic regulation of quiescence in normal T cells will provide insights on the pathobiology of lymphoid malignancies.

The researchers then immunized mice deficient for ELF4 to test their immune response. These mice had a larger memory T cell response, indicating that the absence of ELF4 eliminated control over the proliferation of CD8 T cells.

"If we can control ELF4 activation during vaccination, we can enhance long-term immune response, making a vaccine more effective," Lacorazza said.

"We could enhance in vitro T cell activation of T cells extracted from patients to heighten immune response", said Lacorazza. "In addition, a future line of study is to determine whether deletion of KLF4 expands pre-leukemic clones leading to overt leukemia in pediatric patients".

Lacorazza said these are still hypotheses, but understanding the process that controls T cell proliferation will help in future research.


'/>"/>

Contact: Graciela Gutierrez
ggutierr@bcm.edu
713-798-4710
Baylor College of Medicine
Source:Eurekalert

Related medicine news :

1. The Art of Rhythm Meditation: Zen Buddhist Goes Global with TaKeTiNa Rhythm Process
2. Harvard Medical School Prostate Disease Website Guides Patients Through Decision-Making Process
3. Star Scientific Reports on Filing Patent Application for Zero-Nitrosamine Tobacco Curing Process, Product Development by Rock Creek Pharmaceuticals
4. Scientists discover way to jumpstart bones healing process
5. Leveraging Cloud Computing is the Latest Offering by ICG Consulting to Streamline Costs While Delivering Robust Business Process Solutions
6. Glenwood Systems, LLC Releases EMR Practice Management and Medical Billing Process Improvement Program
7. Pistachio Growers and Processors Announce New Web Site to Inform Consumers, Retailers of Pistachio Brands Not Containing Pistachios From Setton Pistachio of Terra Bella, Inc.
8. Pistachio Growers and Processors Announce New Web Site to Inform Consumers, Retailers of Safe Pistachio Brands
9. VA Continues Notification Process for Veterans Affected by Reprocessing Issues
10. California Association of Health Underwriters Calls Foul Over Partisan Health Care Reform Process
11. Designing the Care-Planning Process to Guide Evidence-Based Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... The American Cleft Palate-Craniofacial Association (ACPA) ... Meeting. KLS is a longtime supporter of the event. , "We are pleased ... Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has a long track ...
(Date:2/23/2017)... Mass. (PRWEB) , ... February 23, 2017 , ... ... as an approved content provider for the National Institute for Health and ... and social care-related organizations in the National Health Service (NHS) to search, order ...
(Date:2/23/2017)... PHILADELPHIA (PRWEB) , ... February 23, 2017 , ... ... risk and uncertainty in clinical trials, today announced that Premier Research, a leading ... management solution. , Clinical trials are becoming increasingly complex, due in part to ...
(Date:2/23/2017)... – , ... ... It’s the perfect opportunity for the nation to come together ... college basketball bracket – with its favorite fruit – apples! ... encouraging apple lovers to join the “Apple Madness” bracket tournament ...
(Date:2/23/2017)... , ... February 23, 2017 , ... HealthPostures, the desk ... an expert sit stand solutions representative to the Minneapolis Home and Garden Show which ... the event that is garnering national attention is the Minneapolis Convention Center. , ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , 23. Februar 2017 Im Rahmen ... nationale Wirtschaftszone in der südwestlichen chinesischen Provinz Guizhou, 2017 mit ... einer Innovationsplattform aktiv an der Entwicklung einer eingebetteten Hightech-Schlüsselindustrie. ... Continue Reading ... ...
(Date:2/23/2017)... Feb. 23, 2017 Regulus Therapeutics Inc ... and development of innovative medicines targeting microRNAs, today announced ... financial results on Thursday, March 2, 2017 after the ... call and webcast on March 2, 2017 at 5:00 ... year 2016 financial results and provide a general business ...
(Date:2/23/2017)... Feb 23, 2017 ... Research and Markets has announced the addition of ... to 2025" report to their offering. The Global ... 1.8% over the next decade to reach approximately $12.8 billion by 2025. ... forecasts for all the given segments on global as well as regional ...
Breaking Medicine Technology: